In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Poster Session 3: Chronic Heart Failure – Treatment
Session

Event : Heart Failure 2019

Topic : Other

  • Session type : Poster Session
  • Date : 27 May 2019
  • Time : 08:30 - 18:00

54 presentations in this session

Effects of mineralocorticoid ceceptor antagonists (MRA) in heart failure patients after up to 12 months of follow-up.

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : LL Buttigieg (Attard,MT)

Sacubitril valsartan, a multicentric experience

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : FJ Cortes (Sevilla,ES)

Effects of sacubitril/valsartan on real-world patients with heart failure due to non-ischemic cardiomyopathy

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : CY Hsu (Taipei City,TW)

Series of patients treated with sacubitril-valsartan in a cardiology day clinic: efficacy and safety after 6 months of follow-up

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : C BELTRAN HERRERA (Madrid,ES)

Microcirculation changes in combination therapy in patients with heart failure with preserved ejection fraction.

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : Z Akhilgova (Moscow,RU)

Sacubitril/valsartan in chronic symptomatic heart failure: a real world experience of delivery and outcomes.

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : A Kearney (Ballymena,GB)

Outpatient inotrope administration in advanced heart failure patients: a single centre experience.

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : J Curtain (Dublin,IE)

Atrial fibrillation in Dutch chronic heart failure with reduced ejection fraction patients: the CHECK-HF registry

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : JF Veenis (Rotterdam,NL)

Reduced diuretic requirements in HFreF patients taking Entresto (ARNI)

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : L O'connor (Dublin,IE)

Sacubitril/Valsartan in real world heart failure proctice in Asia

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : PH Chu (Taipei,TW)

Reduction of loop diuretic requirements in HFrEF patients treated with Sacubitril/Valsartan

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : C Goena Vives (San Sebastian,ES)

Recovery of left ventricular dysfunction after Sacubitril/valsartan: predictors and managements

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : HY Chang (Taipei,TW)

Outcomes of adherence to guideline in heart failure management: the role of heart failure specialist

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : H Skouri (Beirut,LB)

Factors that influence Heart Failure treatment titration in a Heart Failure Unit

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : G Alonso Salinas (Madrid,ES)

Central sleep apnea in patients with chronic heart failure and its treatment with acetazolamide

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : K Sorokina (Moscow,RU)

Effectiveness of early administration of Tolvaptan for cardiac prognosis in acute decompensated heart failure

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : T Kaneda (Yokohama,JP)

Sacubitril/Valsartan: for all patients?

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : B Faria (Guimaraes,PT)

An evaluation of consultant and registrar prescribing in the outpatient setting

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : C Thomson (London,GB)

Frailty quick test, effective for risk stratification of inadequate treatment of heart failure

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : JD Sanchez Vega (Madrid,ES)

Effect of sacubitril/valsartan in real-world patients in South London

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : N Holm (Zurich,CH)

Clinical experience with ambulatory perfusion of levosimendan in an advanced heart failure unit

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : C Moliner (Barcelona,ES)

Study of effect of therapy of chronic obstructive pulmonary disease on coexistent chronic heart failure

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : S Rafla (Alexandria,EG)

Polypharmacy in patients with chronic heart failure

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : MA Gaman (Bucharest,RO)

Changes in hemodynamic profile in patients with severe systolic dysfunction treated with sacubitril-valsartan

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : F Corazza (San Lazzaro Di Savena,IT)

Sacubitril/valsartan inverse remodeling - a prospective echocardiographic study

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : G Bayard (Saint Etienne,FR)

Empagliflozin in heart failure: beyond clinical endpoints

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : S Del Prado Diaz (Madrid,ES)

ARNI use in clinical practice: PARADIGM-HF trial results applied to the real world

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : J AGOSTINHO (Lisboa,PT)

MYK-491, a novel cardiac myosin activator, increases cardiac contractility in healthy volunteers

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : J-F Tamby (San Mateo,US)

Metabolism and pharmacokinetic drug interaction profile of vericiguat, a soluble guanylate cyclase stimulator

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : M Lobmeyer (Wuppertal,DE)

Are we optimizing medical therapy during a heart failure hospitalisation ?

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : K Girard (Sherbrooke,CA)

Sacubitril/Valsartan in clinical practice, how does it work?

Event : Heart Failure 2019

  • Session : Chronic Heart Failure – Treatment
  • Speaker : C Backelin (Goteborg,SE)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are